View Future GrowthHydrapres 과거 순이익 실적과거 기준 점검 0/6Hydrapres 의 수입은 연평균 -46.5%의 비율로 감소해 온 반면, Machinery 산업은 연평균 10.4%의 비율로 증가했습니다. 매출은 연평균 1.8%의 비율로 감소해 왔습니다.핵심 정보-46.51%순이익 성장률-42.19%주당순이익(EPS) 성장률Machinery 산업 성장률12.10%매출 성장률-1.76%자기자본이익률-80.09%순이익률-19.45%다음 순이익 업데이트13 Aug 2026최근 과거 실적 업데이트Reported Earnings • May 21First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: zł8.04m (up 16% from 1Q 2025). Net loss: zł1.17m (loss narrowed 19% from 1Q 2025).공시 • Feb 10Hydrapres S.A. to Report Q4, 2025 Results on Feb 13, 2026Hydrapres S.A. announced that they will report Q4, 2025 results on Feb 13, 2026공시 • Nov 13Hydrapres S.A. to Report Q3, 2025 Results on Nov 14, 2025Hydrapres S.A. announced that they will report Q3, 2025 results on Nov 14, 2025Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł7.77m (down 8.2% from 2Q 2024). Net loss: zł1.15m (loss narrowed 38% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Reported Earnings • Aug 19Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł8.46m (down 14% from 2Q 2023). Net loss: zł1.86m (loss widened 22% from 2Q 2023).Reported Earnings • Feb 16Full year 2023 earnings released: zł0.16 loss per share (vs zł0.03 loss in FY 2022)Full year 2023 results: zł0.16 loss per share (further deteriorated from zł0.03 loss in FY 2022). Revenue: zł37.7m (down 13% from FY 2022). Net loss: zł5.72m (loss widened 429% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updatesNew Risk • Jun 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł4.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł4.2m free cash flow). Earnings have declined by 47% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Market cap is less than US$10m (zł23.4m market cap, or US$6.38m). Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change).공시 • Jun 03Hydrapres S.A., Annual General Meeting, Jun 30, 2026Hydrapres S.A., Annual General Meeting, Jun 30, 2026, at 10:00 Central European Standard Time.Reported Earnings • May 21First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: zł8.04m (up 16% from 1Q 2025). Net loss: zł1.17m (loss narrowed 19% from 1Q 2025).New Risk • Feb 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Market cap is less than US$10m (zł29.6m market cap, or US$8.27m).공시 • Feb 10Hydrapres S.A. to Report Q4, 2025 Results on Feb 13, 2026Hydrapres S.A. announced that they will report Q4, 2025 results on Feb 13, 2026분석 기사 • Dec 30Here's Why Hydrapres (WSE:HPS) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...공시 • Nov 13Hydrapres S.A. to Report Q3, 2025 Results on Nov 14, 2025Hydrapres S.A. announced that they will report Q3, 2025 results on Nov 14, 2025New Risk • Oct 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 47% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.9m free cash flow). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Market cap is less than US$10m (zł27.3m market cap, or US$7.53m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł7.77m (down 8.2% from 2Q 2024). Net loss: zł1.15m (loss narrowed 38% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.분석 기사 • Jun 19Hydrapres (WSE:HPS) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Aug 19Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł8.46m (down 14% from 2Q 2023). Net loss: zł1.86m (loss widened 22% from 2Q 2023).공시 • Jun 05Hydrapres S.A., Annual General Meeting, Jun 28, 2024Hydrapres S.A., Annual General Meeting, Jun 28, 2024.New Risk • May 20New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł3.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.4m free cash flow). Earnings have declined by 81% per year over the past 5 years. Market cap is less than US$10m (zł16.2m market cap, or US$4.13m).Reported Earnings • Feb 16Full year 2023 earnings released: zł0.16 loss per share (vs zł0.03 loss in FY 2022)Full year 2023 results: zł0.16 loss per share (further deteriorated from zł0.03 loss in FY 2022). Revenue: zł37.7m (down 13% from FY 2022). Net loss: zł5.72m (loss widened 429% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.공시 • Jan 17+ 4 more updatesHydrapres S.A. to Report Q3, 2024 Results on Nov 14, 2024Hydrapres S.A. announced that they will report Q3, 2024 results on Nov 14, 2024Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł9.08m (down 22% from 3Q 2022). Net loss: zł1.65m (loss widened zł1.57m from 3Q 2022).Reported Earnings • Aug 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł9.84m (down 11% from 2Q 2022). Net loss: zł1.53m (down 467% from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.공시 • Jun 04Hydrapres S.A., Annual General Meeting, Jun 28, 2023Hydrapres S.A., Annual General Meeting, Jun 28, 2023, at 11:00 Central European Standard Time.Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł10.6m (down 5.1% from 1Q 2022). Net loss: zł1.09m (down zł1.19m from profit in 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 18Full year 2022 earnings released: zł0.03 loss per share (vs zł0.008 profit in FY 2021)Full year 2022 results: zł0.03 loss per share (down from zł0.008 profit in FY 2021). Revenue: zł43.5m (up 34% from FY 2021). Net loss: zł1.08m (down 479% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.공시 • Jan 20+ 3 more updatesHydrapres S.A. to Report Fiscal Year 2022 Results on May 29, 2023Hydrapres S.A. announced that they will report fiscal year 2022 results on May 29, 2023Reported Earnings • Aug 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł11.0m (up 44% from 2Q 2021). Net income: zł417.4k (down 42% from 2Q 2021). Profit margin: 3.8% (down from 9.4% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.공시 • May 27Hydrapres S.A., Annual General Meeting, Jun 24, 2022Hydrapres S.A., Annual General Meeting, Jun 24, 2022, at 12:00 Central European Standard Time.Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.01 (up from zł0.007 in FY 2020). Revenue: zł32.6m (up 24% from FY 2020). Net income: zł363.1k (up 42% from FY 2020). Profit margin: 1.1% (up from 1.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.공시 • Jan 30+ 4 more updatesHydrapres S.A. to Report Fiscal Year 2021 Results on May 27, 2022Hydrapres S.A. announced that they will report fiscal year 2021 results on May 27, 2022Reported Earnings • Aug 19Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł7.65m (up 51% from 2Q 2020). Net income: zł716.7k (up zł892.6k from 2Q 2020). Profit margin: 9.4% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 17Full year 2020 earnings released: EPS zł0.007 (vs zł0.007 in FY 2019)The company reported a soft full year result with weaker earnings and revenues, although profit margins were improved. Full year 2020 results: Revenue: zł26.4m (down 30% from FY 2019). Net income: zł256.3k (down 4.6% from FY 2019). Profit margin: 1.0% (up from 0.7% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Feb 10New 90-day high: zł0.42The company is up 15% from its price of zł0.36 on 10 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Machinery industry, which is up 33% over the same period.공시 • Jan 16+ 4 more updatesHydrapres S.A. to Report Q3, 2021 Results on Nov 10, 2021Hydrapres S.A. announced that they will report Q3, 2021 results on Nov 10, 2021Is New 90 Day High Low • Jan 07New 90-day high: zł0.40The company is up 6.0% from its price of zł0.37 on 09 October 2020. The Polish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 22% over the same period.Is New 90 Day High Low • Oct 02New 90-day low: zł0.32The company is down 13% from its price of zł0.37 on 01 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 1.0% over the same period.매출 및 비용 세부 내역Hydrapres가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이WSE:HPS 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Mar 2630-65031 Dec 2529-65030 Sep 2531-55030 Jun 2532-55031 Mar 2533-64031 Dec 2434-54030 Sep 2433-64030 Jun 2434-64031 Mar 2435-64031 Dec 2338-64030 Sep 2339-64030 Jun 2342-44031 Mar 2343-23031 Dec 2244-13030 Sep 224203030 Jun 223903031 Mar 223503031 Dec 213303030 Sep 213213030 Jun 213013031 Mar 212703031 Dec 202603030 Sep 202903030 Jun 203103031 Mar 203613031 Dec 193803030 Sep 193813030 Jun 193803031 Mar 194113031 Dec 184313030 Sep 184613030 Jun 184803031 Mar 1849-13031 Dec 1750-13030 Sep 1750-23030 Jun 1750-13031 Mar 175013031 Dec 1651-13030 Sep 165413030 Jun 165313031 Mar 1651-13031 Dec 155003030 Sep 154403030 Jun 1541030양질의 수익: HPS 은(는) 현재 수익성이 없습니다.이익 마진 증가: HPS는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: HPS은 수익성이 없으며 지난 5년 동안 손실이 연평균 46.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 HPS의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: HPS은 수익성이 없어 지난 해 수익 성장률을 Machinery 업계(-7.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: HPS는 현재 수익성이 없으므로 자본 수익률이 음수(-80.09%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCapital-goods 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/23 21:19종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hydrapres S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 21First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: zł8.04m (up 16% from 1Q 2025). Net loss: zł1.17m (loss narrowed 19% from 1Q 2025).
공시 • Feb 10Hydrapres S.A. to Report Q4, 2025 Results on Feb 13, 2026Hydrapres S.A. announced that they will report Q4, 2025 results on Feb 13, 2026
공시 • Nov 13Hydrapres S.A. to Report Q3, 2025 Results on Nov 14, 2025Hydrapres S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł7.77m (down 8.2% from 2Q 2024). Net loss: zł1.15m (loss narrowed 38% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 19Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł8.46m (down 14% from 2Q 2023). Net loss: zł1.86m (loss widened 22% from 2Q 2023).
Reported Earnings • Feb 16Full year 2023 earnings released: zł0.16 loss per share (vs zł0.03 loss in FY 2022)Full year 2023 results: zł0.16 loss per share (further deteriorated from zł0.03 loss in FY 2022). Revenue: zł37.7m (down 13% from FY 2022). Net loss: zł5.72m (loss widened 429% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.
New Risk • Jun 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł4.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł4.2m free cash flow). Earnings have declined by 47% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Market cap is less than US$10m (zł23.4m market cap, or US$6.38m). Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change).
공시 • Jun 03Hydrapres S.A., Annual General Meeting, Jun 30, 2026Hydrapres S.A., Annual General Meeting, Jun 30, 2026, at 10:00 Central European Standard Time.
Reported Earnings • May 21First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: zł8.04m (up 16% from 1Q 2025). Net loss: zł1.17m (loss narrowed 19% from 1Q 2025).
New Risk • Feb 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Market cap is less than US$10m (zł29.6m market cap, or US$8.27m).
공시 • Feb 10Hydrapres S.A. to Report Q4, 2025 Results on Feb 13, 2026Hydrapres S.A. announced that they will report Q4, 2025 results on Feb 13, 2026
분석 기사 • Dec 30Here's Why Hydrapres (WSE:HPS) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
공시 • Nov 13Hydrapres S.A. to Report Q3, 2025 Results on Nov 14, 2025Hydrapres S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
New Risk • Oct 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 47% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł1.9m free cash flow). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Market cap is less than US$10m (zł27.3m market cap, or US$7.53m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: zł7.77m (down 8.2% from 2Q 2024). Net loss: zł1.15m (loss narrowed 38% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
분석 기사 • Jun 19Hydrapres (WSE:HPS) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Aug 19Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł8.46m (down 14% from 2Q 2023). Net loss: zł1.86m (loss widened 22% from 2Q 2023).
공시 • Jun 05Hydrapres S.A., Annual General Meeting, Jun 28, 2024Hydrapres S.A., Annual General Meeting, Jun 28, 2024.
New Risk • May 20New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł3.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł3.4m free cash flow). Earnings have declined by 81% per year over the past 5 years. Market cap is less than US$10m (zł16.2m market cap, or US$4.13m).
Reported Earnings • Feb 16Full year 2023 earnings released: zł0.16 loss per share (vs zł0.03 loss in FY 2022)Full year 2023 results: zł0.16 loss per share (further deteriorated from zł0.03 loss in FY 2022). Revenue: zł37.7m (down 13% from FY 2022). Net loss: zł5.72m (loss widened 429% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.
공시 • Jan 17+ 4 more updatesHydrapres S.A. to Report Q3, 2024 Results on Nov 14, 2024Hydrapres S.A. announced that they will report Q3, 2024 results on Nov 14, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł9.08m (down 22% from 3Q 2022). Net loss: zł1.65m (loss widened zł1.57m from 3Q 2022).
Reported Earnings • Aug 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł9.84m (down 11% from 2Q 2022). Net loss: zł1.53m (down 467% from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.
공시 • Jun 04Hydrapres S.A., Annual General Meeting, Jun 28, 2023Hydrapres S.A., Annual General Meeting, Jun 28, 2023, at 11:00 Central European Standard Time.
Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł10.6m (down 5.1% from 1Q 2022). Net loss: zł1.09m (down zł1.19m from profit in 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 18Full year 2022 earnings released: zł0.03 loss per share (vs zł0.008 profit in FY 2021)Full year 2022 results: zł0.03 loss per share (down from zł0.008 profit in FY 2021). Revenue: zł43.5m (up 34% from FY 2021). Net loss: zł1.08m (down 479% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
공시 • Jan 20+ 3 more updatesHydrapres S.A. to Report Fiscal Year 2022 Results on May 29, 2023Hydrapres S.A. announced that they will report fiscal year 2022 results on May 29, 2023
Reported Earnings • Aug 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł11.0m (up 44% from 2Q 2021). Net income: zł417.4k (down 42% from 2Q 2021). Profit margin: 3.8% (down from 9.4% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.
공시 • May 27Hydrapres S.A., Annual General Meeting, Jun 24, 2022Hydrapres S.A., Annual General Meeting, Jun 24, 2022, at 12:00 Central European Standard Time.
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.01 (up from zł0.007 in FY 2020). Revenue: zł32.6m (up 24% from FY 2020). Net income: zł363.1k (up 42% from FY 2020). Profit margin: 1.1% (up from 1.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
공시 • Jan 30+ 4 more updatesHydrapres S.A. to Report Fiscal Year 2021 Results on May 27, 2022Hydrapres S.A. announced that they will report fiscal year 2021 results on May 27, 2022
Reported Earnings • Aug 19Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł7.65m (up 51% from 2Q 2020). Net income: zł716.7k (up zł892.6k from 2Q 2020). Profit margin: 9.4% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 17Full year 2020 earnings released: EPS zł0.007 (vs zł0.007 in FY 2019)The company reported a soft full year result with weaker earnings and revenues, although profit margins were improved. Full year 2020 results: Revenue: zł26.4m (down 30% from FY 2019). Net income: zł256.3k (down 4.6% from FY 2019). Profit margin: 1.0% (up from 0.7% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Feb 10New 90-day high: zł0.42The company is up 15% from its price of zł0.36 on 10 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Machinery industry, which is up 33% over the same period.
공시 • Jan 16+ 4 more updatesHydrapres S.A. to Report Q3, 2021 Results on Nov 10, 2021Hydrapres S.A. announced that they will report Q3, 2021 results on Nov 10, 2021
Is New 90 Day High Low • Jan 07New 90-day high: zł0.40The company is up 6.0% from its price of zł0.37 on 09 October 2020. The Polish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 22% over the same period.
Is New 90 Day High Low • Oct 02New 90-day low: zł0.32The company is down 13% from its price of zł0.37 on 01 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 1.0% over the same period.